Inmune Bio INMB
NASDAQ INMB
$1.10 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Inmune Bio (INMB) Capital Leases (2021 - 2025)

Updated

Analysis

Inmune Bio (INMB) Capital Leases (2021 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Inmune Bio 30.71 Mn -50.14 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 347,000.00
Dec 31, 2024 384,000.00
Sep 30, 2024 419,000.00
Mar 31, 2024 485,000.00
Dec 31, 2023 516,000.00
Dec 31, 2021 419,000.00
API Access

Inmune Bio Capital Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-leases&ticker=INMB&period=max&api_key=YOUR_API_KEY